HLA Peptide Binding Services

Prediction algorithms can flag hundreds of candidate peptides, but only a fraction will actually bind their target HLA molecule with the affinity needed to drive a genuine T cell response and become true epitopes.

HLA Protein Technologies' Peptide Binding Services put real biochemical data behind every peptide candidate before it is used in T cell research. Using fluorescence polarization-based competitive binding assays and our own soluble, natively folded HLA proteins, we directly measure how strongly a candidate binds a specific HLA allele with fast, quantitative, reproducible results.

Whether you need to screen a full peptide library, validate a handful of high-priority candidates, or map every potential T cell epitope across a protein of interest, our services are built to eliminate guesswork, filter out the false positives and negatives introduced by prediction algorithms, and get you to a high-affinity epitope target faster.

Results in as little as 3 days. Backed by 25+ years of HLA expertise.

Peptide Epitope Validation

Confirm the binding affinity (IC50) of individual candidate peptides to properly rank and prioritize their immunogenic potential.

Peptide Epitope Screening

Screen focused peptide libraries to identify top-ranking binders and eliminate non-binders, accelerating discovery and saving resources.

T cell Epitope Mapping

Generate a full epitope map for any protein of interest across a broad panel of HLA alleles using a high-throughput approach.

Peptide Epitope Validation

Competition based peptide binding assay methodologies have become exceedingly popular for assessing the ability of synthetically defined peptide epitopes to associate with specific HLA complexes. This has been accomplished by determining their half maximal inhibitory concentration (IC50) as a measure of the effectiveness of inhibiting test peptides to judge their immunogenic potential and value in the development of novel immunotherapies.

Advance qualified peptide candidates quickly by validating your screening candidates or predicted epitopes by confirming their affinity and ranking order.

Fluoresence polarization-based competition assay to determine the IC50 of soluble HLA to specific peptides
Screening results of HLA peptide affinity

Peptide Epitope Screening

The peptide epitope screening system interrogates peptide libraries with variable sequence data. HLA Protein Technologies Inc’s screening system identifies epitope candidates and properly prioritizes these newly found potential T-cell epitopes according to their HLA affinity. Peptide epitope screening efforts are primarily applied to eliminate false positive and negative results generated by computer algorithms. The screening system also resolves restriction elements and allows researchers to compare variable and conserved regions of different clades of a virus.

T Cell Epitope Mapping

T cell epitope mapping has emerged as one of the most powerful new drug discovery tools for a range of biomedical applications. Our mapping service is a high-throughput approach, which allows the creation of individual epitope maps for any protein of interest. This application enables the screening of large libraries of overlapping peptides with a broad selection of HLA alleles to identify high affinity binding peptides and the selection of the most potent T cell epitope candidates.

Epitope mapping of influenza peptides

Fluorescence Polarization Technology

Fluorescence polarization (FP) is unique among methods used to analyze molecular binding events because it allows the instantaneous measurement of the ratio between free and bound labeled ligand in solution without any separation steps. The technology is based on the principle that if a fluorescent-labeled peptide binds to a sHLA molecule of higher molecular weight, polarization values will increase due to the slower molecular rotation of the bound probe.

Competitive Assay Technology

To elaborate the fast and precise molecular binding of a peptide to an HLA molecule, a reference fluorescent-labeled peptide is incubated with activated sHLA in the presence of a peptide competitor and peptide/HLA interaction is monitored over time. Only a simple three step process is required to perform the assay. The activation step (1) is forcing the folded structure into a temporary state of instability, making it amenable for the competitor peptide to be inserted into the groove. The mixing step (2) is providing a fluorescent-labeled tracer peptide (yellow) and test peptide (blue) for competition. And lastly, the measuring step (3) where data is collected, and a positive response will occur when the peptide of interest outcompetes the labeled peptide tracer. A negative response will take place when the peptide of interest has no binding characteristics and only the tracer is assembling with the sHLA.

Fluorsence polarization binding assay

You might also be interested in...

Soluble HLA Class II Proteins

Mammalian produced, zipper stabilized, endogenously loaded, and naturally folded recombinant soluble HLA Class II proteins

Soluble HLA Class I Proteins

Mammalian produced, endogenously loaded, and naturally folded recombinant soluble HLA Class I proteins

Soluble HLA Technology

Learn more about our sHLA Technology and how it can improve the quality and speed of your science